Displaying items by tag: department of neurology

The eye is a window to the brain; scientists discover early signs of dementia in changes to neurons in the eye’s retina.

UAB is the first medical center in the Southeast to implant a new type of electrical stimulator to control seizures in patients with epilepsy.
Research in personalized medicine, health informatics and genomic medicine spans disciplines and will impact the treatment of many diseases.
New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.
Anthony Nicholas, M.D., associate professor in the Department of Neurology at the University of Alabama at Birmingham, is a co-editor of the first textbook on the subject of protein deimination in human health and disease.
A new UAB clinic can predict risk for developing Alzheimer’s disease and offer strategies to reduce that risk.
As part of its ongoing Science, Communication and Innovation talks, Lucas Pozzo-Miller will speak about Rett syndrome.
A new NIH grant could allow researchers to better predict risk factors for patients using blood-thinners by examining the influence of genes, lifestyle, clinical factors and environment.
Parkinson’s disease awareness is highlighted with official recognition from Alabama and the city of Birmingham in April.
Learn about Lou Gehrig’s disease at the second UAB Neuroscience Café at the Hoover Library.
UAB has teamed with the Michael J. Fox Foundation to look for genetic biomarkers for Parkinson’s disease.
Neuroscience Café serves healthy portions of fascinating topics in the field of neuroscience at 6:30 p.m. on the third Monday of every month.
Researchers at UAB show that high-intensity strength training improves mobility, mood and overall quality of life for Parkinson’s patients.
CNET promotes the discovery of novel treatments for neurodegenerative disorders, teaches scientists and clinicians about these diseases, and facilitates the application of these discoveries to the clinical care of patients.
Gel form of a medication for Parkinson’s disease speeds response time over traditional pills.
This group, newly established as an AES committee, is charged with promoting and tracking progress in areas targeted as potential epilepsy benchmarks by NINDS.
Page 11 of 13